<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721718</url>
  </required_header>
  <id_info>
    <org_study_id>MERS-002</org_study_id>
    <nct_id>NCT03721718</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers</brief_title>
  <official_title>Phase I/IIa, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of GLS-5300, Administered ID Followed by CELLECTRA® 2000 (Electroporation, EP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneOne Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Vaccine Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneOne Life Science, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Middle East Respiratory Syndrome Coronavirus (MERS CoV), is a cause of severe and highly&#xD;
      fatal lower respiratory tract infection, first identified in 2012. As of August 2018, there&#xD;
      have been 2229 cases reported with a case fatality rate &gt;35%. In 2015 an individual returning&#xD;
      to South Korea served as the index case for an outbreak of 186 individuals, of who, &gt;20%&#xD;
      died. GLS-5300 is a DNA plasmid vaccine that expresses the MERS CoV spike (S) glycoprotein.&#xD;
      This Phase I/IIa study will evaluate the safety, tolerability and immunogenicity of GLS-5300&#xD;
      administered intradermally (ID) followed by electroporation at 0.3 and 0.6 mg/dose assessing&#xD;
      2 and 3-dose regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GLS-5300 is a DNA plasmid vaccine that expresses the MERS CoV spike (S) glycoprotein.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Actual">April 22, 2020</completion_date>
  <primary_completion_date type="Actual">May 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Day0 through up to 60 weeks</time_frame>
    <description>Incidence of Adverse events by System organ class (SOC); preferred term (PT); severity and relationship to study treatment and schedule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Administration (injection) site reactions</measure>
    <time_frame>Day0 through up to 60 weeks</time_frame>
    <description>Administration (injection) site reactions described by frequency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in safety laboratory parameters</measure>
    <time_frame>Day0 through up to 60 weeks</time_frame>
    <description>Number of participants with changes based on frequency in safety lab parameters in Complete Blood Count and Liver panel tests&quot; or similar.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Administration (injection) site pain</measure>
    <time_frame>Administration (injection) site pain</time_frame>
    <description>Administration (injection) site pain as described by Visual Analog Scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular Immune Responses</measure>
    <time_frame>Day0 through up to 60 weeks</time_frame>
    <description>Antigen specific cellular immune responses to MERS-CoV as determined by Interferon-gamma (IFN-γ) ELISpot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binding antibody titers</measure>
    <time_frame>Day0 through up to 60 weeks</time_frame>
    <description>Binding antibody titers against MERS-CoV for a 2 and 3 dose vaccination regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibodies</measure>
    <time_frame>Day0 through up to 60 weeks</time_frame>
    <description>Titers of neutralizing antibodies against MERS-CoV</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLS-5300 with ID Cellectra electroporation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLS-5300 at 0.3mg DNA/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLS-5300 at 0.3mg DNA/dose with ID Cellectra electroporation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLS-5300 at 0.3mg DNA/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLS-5300 at 0.6mg DNA/dose (3 dose regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLS-5300 at 0.6mg DNA/dose (2 dose regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GLS-5300</intervention_name>
    <description>[Part A] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) [Part B] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)</description>
    <arm_group_label>GLS-5300 at 0.3mg DNA/dose with ID Cellectra electroporation</arm_group_label>
    <arm_group_label>GLS-5300 at 0.6mg DNA/dose (2 dose regimen)</arm_group_label>
    <arm_group_label>GLS-5300 at 0.6mg DNA/dose (3 dose regimen)</arm_group_label>
    <arm_group_label>GLS-5300 with ID Cellectra electroporation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cellectra 2000 Electroporation</intervention_name>
    <description>GLS-5300 administered ID followed by Cellectra 2000 Electroporation</description>
    <arm_group_label>GLS-5300 at 0.3mg DNA/dose with ID Cellectra electroporation</arm_group_label>
    <arm_group_label>GLS-5300 at 0.6mg DNA/dose (2 dose regimen)</arm_group_label>
    <arm_group_label>GLS-5300 at 0.6mg DNA/dose (3 dose regimen)</arm_group_label>
    <arm_group_label>GLS-5300 with ID Cellectra electroporation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 19-70 years;&#xD;
&#xD;
          2. Able to provide consent to participate and having signed an Informed Consent Form&#xD;
             (ICF);&#xD;
&#xD;
          3. Able and willing to comply with all study procedures;&#xD;
&#xD;
          4. Women of child-bearing potential agree to either remain sexually abstinent, use&#xD;
             medically effective contraception (oral contraception, barrier methods, spermicide,&#xD;
             etc.) or have a partner who is sterile during this trials , or have a partner who is&#xD;
             medically unable to induce pregnancy.&#xD;
&#xD;
          5. Normal screening ECG or screening ECG with no clinically significant findings;&#xD;
&#xD;
          6. Screening laboratory must be within normal limits or have only Grade 0-1 findings;&#xD;
&#xD;
          7. No history of clinically significant immunosuppressive or autoimmune disease.&#xD;
&#xD;
          8. Not currently or within the previous 4 weeks taking immunosuppressive agents&#xD;
             (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose&#xD;
             methotrexate, or prednisone at a dose less than or equal to 10 mg/day or steroid&#xD;
             equivalent).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Administration of an investigational compound either currently or within 90 days of&#xD;
             first dose;&#xD;
&#xD;
          2. Previous receipt of an investigational product for the treatment or prevention of&#xD;
             MERS-CoV or SARS-CoV except if subject is verified to have received placebo;&#xD;
&#xD;
          3. Previous infection with MERS-CoV;&#xD;
&#xD;
          4. Administration of any vaccine within 4 weeks of first dose;&#xD;
&#xD;
          5. Administration of any monoclonal or polyclonal antibody product within 4 weeks of the&#xD;
             first dose&#xD;
&#xD;
          6. Administration of any blood product within 3 months of first dose;&#xD;
&#xD;
          7. Pregnancy or breast feeding or plans to become pregnant during the course of the&#xD;
             study;&#xD;
&#xD;
          8. History of positive serologic test for HIV, hepatitis B surface antigen (HBsAg); or&#xD;
             any potentially communicable infectious disease as determined by the Principal&#xD;
             Investigator or Medical Monitor;&#xD;
&#xD;
          9. Positive serologic test for HIV, Hepatitis B surface antigen, or hepatitis C&#xD;
             (exception: successful treatment with confirmation of sustained virologic response);&#xD;
&#xD;
         10. Baseline evidence of kidney disease as measured by creatinine greater than 1.5mg/dL&#xD;
             (CKD Stage II or greater);&#xD;
&#xD;
         11. Baseline screening lab(s) with Grade 2 or higher abnormality;&#xD;
&#xD;
         12. Chronic liver disease or cirrhosis;&#xD;
&#xD;
         13. Immunosuppressive illness including hematologic malignancy, history of solid organ or&#xD;
             bone marrow transplantation;&#xD;
&#xD;
         14. Current or anticipated concomitant immunosuppressive therapy (excluding inhaled,&#xD;
             topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or&#xD;
             prednisone at a dose greater than 10 mg/day or steroid equivalent);&#xD;
&#xD;
         15. Past (within 6 months), current or anticipated treatment with TNF-α inhibitors such as&#xD;
             infliximab, adalimumab, etanercept, or other monoclonal antibody;&#xD;
&#xD;
         16. Prior major surgery or any radiation therapy within 4 weeks of group assignment;&#xD;
&#xD;
         17. Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome; history of PSVT&#xD;
             syndrome, history of prolonged QT syndrome;&#xD;
&#xD;
         18. Presence of a cardiac pacemaker or automatic implantable cardioverter defibrillator&#xD;
             (AICD);&#xD;
&#xD;
         19. Metal implants within 20 cm of the planned site(s) of injection;&#xD;
&#xD;
         20. Presence of keloid scar formation or hypertrophic scar as a clinically significant&#xD;
             medical condition at the planned site(s) of injection.&#xD;
&#xD;
         21. Prisoner or subjects who are compulsorily detained (involuntary incarceration) for&#xD;
             treatment of either a physical or psychiatric illness;&#xD;
&#xD;
         22. Active drug or alcohol use or dependence that, in the opinion of the investigator,&#xD;
             would interfere with adherence to study requirements or assessment of immunologic&#xD;
             endpoints;&#xD;
&#xD;
         23. Not willing to allow storage and future use of samples for MERS-CoV related research&#xD;
&#xD;
         24. Any illness or condition that in the opinion of the investigator may affect the safety&#xD;
             of the subject or the evaluation of any study endpoint.&#xD;
&#xD;
         25. Presence of tattoos covering all possible injection sites.&#xD;
&#xD;
         26. Healthcare workers participating in the medical examination of patients infection with&#xD;
             MER&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Maslow, MD, PhD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>GeneOne Life Science, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MERS CoV</keyword>
  <keyword>MERS-CoV</keyword>
  <keyword>Middle East Respiratory Syndrome</keyword>
  <keyword>MERS</keyword>
  <keyword>DNA Vaccine</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

